Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prognostic Factors and Outcomes in Patients with Guillain-Barré Syndrome Requiring Invasive Mechanical Ventilation
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
086

To determine clinical and electrophysiological prognostic factors for invasive mechanical ventilation (IMV) in patients with GBS.

Almost a third of patients with Guillain-Barré Syndrome (GBS) require mechanical ventilation, increasing mortality by 15-30% and proving poor functional outcomes. 
A cross-sectional study was carried out in a referral center in Mexico City, from January 2015 to December 2019. Baseline demographics, MRC, Hughes, EGRIS, dysautonomia and nerve conduction studies were performed in GBS patients requiring IMV. A multivariate analysis for IMV and a survival analysis for independent walk in prolonged-IMV (>14 days) were performed.

Forty-nine (32%) out of 153 GBS patients required IMV. Statistically significant prognostic factors for IMV were deltoid muscle strength ≤2 [OR 7.1 (1.6-31.1)], EGRIS [OR 2.5 (1.3-4.6)] and autonomic dysfunction [OR 6.6 (2.0-22.0)].  The prevalence of electrodecrement <1mV in the compound muscle action potential (CMAP) of distal motor median nerve was higher in prolonged-IMV (44.8% vs 21%, p=0.049). A significant minor prevalence of prolonged-IMV patients regain independent walk at 6 months using the Kaplan-Meier method (log rank test p<0.001).  
We provide new specific clinical (deltoid muscle strength and autonomic dysfunction) and electrophysiological variables to discriminate GBS patients that will require IMV.
Authors/Disclosures
Adib Jorge De Sarachaga, MD (Instituto Nacional De Neurologia Y Neurocirugia Manuel Velasco Suarez)
PRESENTER 		Dr. Jorge De Sarachaga has nothing to disclose.
No disclosure on file
Maria Eugenia Briseño Godinez No disclosure on file
No disclosure on file
No disclosure on file
Anna L. Bazan, MD (Instituto Nacional de Neurologia) Dr. Bazan has nothing to disclose.
Javier A. Galnares-Olalde, Jr., MD (Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez) Dr. Galnares-Olalde has nothing to disclose.
Elizabeth Leon Elizabeth Leon has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for BIOGEN AND SANOFI.
Edwin S. Vargas, MD (National Institute of Neurology, Mexico) Dr. Vargas has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Vargas has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for CSL Berhing.